Viewing Study NCT00141102



Ignite Creation Date: 2024-05-05 @ 11:50 AM
Last Modification Date: 2024-10-26 @ 9:14 AM
Study NCT ID: NCT00141102
Status: COMPLETED
Last Update Posted: 2021-03-03
First Post: 2005-08-29

Brief Title: Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal GI Safety In High GI Risk Patients With Arthritis
Sponsor: Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization: Pfizer

Study Overview

Official Title: Double-Blind Triple Dummy Parallel-Group Randomized Six-Month Study To Compare Celecoxib 200 Mg BID With Diclofenac Sr 75 Mg BID Plus Omeprazole 20 Mg QD For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events
Status: COMPLETED
Status Verified Date: 2021-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: CONDOR
Brief Summary: To determine whether celecoxib is superior to combined therapy with diclofenac and omeprazole in the incidence of clinically significant upper andor lower gastrointestinal GI events in high GI risk subjects with osteoarthritis andor rheumatoid arthritis
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None